Cargando…

Implications of Withaferin A in neurological disorders

Detalles Bibliográficos
Autores principales:	Ram, Natasha, Peak, Stephanie L., Perez, Andres R., Jinwal, Umesh K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896225/ https://www.ncbi.nlm.nih.gov/pubmed/32859786 http://dx.doi.org/10.4103/1673-5374.290894

Ejemplares similares

Data from SILAC-based quantitative analysis of lysates from mouse microglial cells treated with Withaferin A (WA)
por: Narayan, Malathi, et al.
Publicado: (2016)

N-acetyl proline-glycine-proline: implications for neurological disorders
por: Hill, Jeff W., et al.
Publicado: (2016)

The left-right side-specific endocrine signaling: implications for neurological deficits in stroke and neurodevelopmental disorders
por: Bakalkin, Georgy, et al.
Publicado: (2022)

Neurological Dysfunction in Long COVID Should Not Be Labelled as Functional Neurological Disorder
por: Van der Feltz-Cornelis, Christina M., et al.
Publicado: (2023)

Repurposing niclosamide for the treatment of neurological disorders
por: Apolloni, Savina, et al.
Publicado: (2023)

Studying neurological disorders using induced pluripotent stem cells and optogenetics
por: Chin, Eunice W.M., et al.
Publicado: (2015)

Progress in mimicking brain microenvironments to understand and treat neurological disorders
por: Ngo, Mai T., et al.
Publicado: (2021)

Multi-targeted anti-inflammatory drugs for the treatment of neurological disorders
por: Lui, Austin, et al.
Publicado: (2022)

Disease-directed engineering for physiology-driven treatment interventions in neurological disorders
por: Wood, Thomas, et al.
Publicado: (2019)

Augmentation of transforming growth factor-β signaling for the treatment of neurological disorders
por: Luo, Jian
Publicado: (2023)

Could mammalian inorganic polyphosphate be a crucial signaling molecule in neurological disorders?
por: Da Costa, Renata Torres, et al.
Publicado: (2023)

Early life stress-induced neuroinflammation and neurological disorders: a novel perspective for research
por: Catale, Clarissa, et al.
Publicado: (2022)

Looking beyond the hippocampus: old and new neurological targets for understanding memory disorders
por: Aggleton, John P.
Publicado: (2014)

Programmable macromolecule-based RNA-targeting therapies to treat human neurological disorders
por: Morelli, Kathryn H., et al.
Publicado: (2023)

Evidence-Based Mind-Body Interventions for Children and Adolescents with Functional Neurological Disorder
por: Kozlowska, Kasia, et al.
Publicado: (2023)

Withaferin A Suppresses Beta Amyloid in APP Expressing Cells: Studies for Tat and Cocaine Associated Neurological Dysfunctions
por: Tiwari, Sneham, et al.
Publicado: (2018)

Estimation of Withaferin-A by HPLC and standardization of the Ashwagandhadi lehyam formulation
por: Meena, Ajay Kumar, et al.
Publicado: (2021)

Pesticides and Neurologic Symptoms
por: Burns, Carol, et al.
Publicado: (2005)

Transcranial electrical stimulation in neurological disease
por: Brown, Gregory L., et al.
Publicado: (2022)

Convergence of human and veterinary medicine: leveraging canine naturally occurring neurological disorders to develop regenerative treatments
por: Clark, Kaitlin C., et al.
Publicado: (2022)

Withaferin A Associated Differential Regulation of Inflammatory Cytokines
por: Dubey, Seema, et al.
Publicado: (2018)

Evaluation of the geroprotective effects of withaferin A in Drosophila melanogaster
por: Koval, Liubov, et al.
Publicado: (2021)

Withaferin A is a Leptin Sensitizer with Strong Anti-Diabetic Properties in Mice
por: Lee, Jaemin, et al.
Publicado: (2016)

Withaferin A attenuates ovarian cancer-induced cardiac cachexia
por: Kelm, Natia Q., et al.
Publicado: (2020)

Withaferin A: From Ancient Remedy to Potential Drug Candidate
por: Sultana, Tahira, et al.
Publicado: (2021)

Packages of Care for Mental, Neurological, and Substance Use Disorders in Low- and Middle-Income Countries: PLoS Medicine Series
por: Patel, Vikram, et al.
Publicado: (2009)

Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo
por: Yang, Huanjie, et al.
Publicado: (2012)

Lipid mediators of inflammation in neurological injury: shifting the balance toward resolution
por: Harrison, Jordan L., et al.
Publicado: (2016)

Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop
por: Stephenson, Diane, et al.
Publicado: (2023)

Evaluating anticancer properties of Withaferin A—a potent phytochemical
por: Atteeq, Maushma
Publicado: (2022)

Withaferin A for COVID-19: a Network Pharmacology Approach
por: Mishra, Ashasmita S., et al.
Publicado: (2023)

Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling
por: Straughn, Alex R., et al.
Publicado: (2019)

Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
por: Behl, Tapan, et al.
Publicado: (2020)

Withania Somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology
por: Dutta, Rinku, et al.
Publicado: (2019)

Withaferin A inhibits ferroptosis and protects against intracerebral hemorrhage
por: Zhou, Zi-Xian, et al.
Publicado: (2022)

Safety, toxicity and pharmacokinetic assessment of oral Withaferin-A in mice
por: Gupta, Saurabh Kumar, et al.
Publicado: (2022)

Pesticides and Neurologic Symptoms: Kamel et al. Respond
por: Kamel, Freya, et al.
Publicado: (2005)

Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass
por: Straughn, Alex R., et al.
Publicado: (2021)

Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model
por: Suman, Suman, et al.
Publicado: (2016)

Correction: Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo
por: Yang, Huanjie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6b290p2r1sro38vakj29025u75